Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
HaematologicaPublished 8 December 2009Open access
Tom Lenaerts, Jorge M. Pacheco, Arne Traulsen, David Dingli
Citations70
SJR quartileQ1
SJR score2.45
SNIP1.50
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia, although it may have to be prolonged and the depth of response increases with time in the vast majority of patients, illustrating the importance of stochastic effects on the dynamics of acquired hematopoietic stem cell disorders.
Abstract
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia, although it may have to be prolonged. The depth of response increases with time in the vast majority of patients. These results illustrate the importance of stochastic effects on the dynamics of acquired hematopoietic stem cell disorders and have direct relevance for other hematopoietic stem cell-derived diseases.
Keywords
Medicine
New England Journal of MedicineFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
3,481 Citations2006Brian Druker, François Guilhot +30 more
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
ScienceInduction of Chronic Myelogenous Leukemia in Mice by the P210 <sup> <i>bcr/abl</i> </sup> Gene of the Philadelphia Chromosome
2,182 Citations1990George Q. Daley, Richard A. Van Etten +1 more
It is demonstrated that P210bcr/abl expression can induce chronic myelogenous leukemia and retrovirus-mediated expression of the protein provides a murine model system for further analysis of the disease.
New England Journal of MedicineGranulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML
1,484 Citations2004Catriona Jamieson, Laurie Ailles +10 more
Activation of beta-catenin in CML granulocyte-macrophage progenitors appears to enhance the self-renewal activity and leukemic potential of these cells.
NatureIFNα activates dormant haematopoietic stem cells in vivo
1,356 Citations2009Marieke Essers, Sandra Offner +5 more
It is shown that in response to treatment of mice with interferon-α (IFNα), HSCs efficiently exit G0 and enter an active cell cycle, raising the possibility for new applications of type I interferons to target cancer stem cells.
BloodPrimitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
1,185 Citations2002Susan M. Graham, Heather G. Jørgensen +5 more
In vitro insensitivity to STI571, in combination with its demonstrated antiproliferative activity, could translate into disease relapse after prolonged therapy despite dramatic short-term responses in vivo.
New England Journal of MedicineChronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
949 Citations2003John M. Goldman, Junia V. Melo
This review brings the reader up to date on recent advances in understanding the biology of CML and how they have changed the management of the disease.
CellDevelopmental potential and dynamic behavior of hematopoietic stem cells
882 Citations1986Ihor R. Lemischka, David H. Raulet +1 more
NatureDynamics of chronic myeloid leukaemia
850 Citations2005Franziska Michor, Timothy P. Hughes +5 more
A four-compartment model, based on the known biology of haematopoietic differentiation, can explain the kinetics of the molecular response to imatinib in a 169-patient data set and provides the first quantitative insights into the in vivoKinetics of a human cancer.
BloodMolecular biology of bcr-abl1–positive chronic myeloid leukemia
759 Citations2008Alfonso Quintás‐Cardama, Jörge E. Cortes
Primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, still remain poorly understood are synthesized.
Cancer CellMOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
699 Citations2004Brian J.P. Huntly, Hirokazu Shigematsu +10 more
It is demonstrated that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death.
BloodImatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
530 Citations2006Philippe Rousselot, Françoise Huguet +11 more
It is hypothesized that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells, which may be eradicated or controlled in long-term nonrelapsing patients, as described in the study.
LeukemiaFrequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
387 Citations2006Elias Jabbour, Hagop M. Kantarjian +11 more
P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial, and development of clonal evolution and higher percentage of peripheral blood basophils were associated with worse survival from the time ofImatinib failure.
Nature MedicineDynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
340 Citations2006Ingo Roeder, Matthias Horn +4 more
This work shows for two independent datasets that clinically observed BCR-ABL1 transcript dynamics during imatinib treatment of CML can consistently be explained by a selective functional effect ofImatinib on proliferative leukemia stem cells, and suggests the general potential of imatin ib to induce a complete elimination of the malignant clone.
Proceedings of the National Academy of SciencesMathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer
287 Citations2007Matthew D. Johnston, Carina M. Edwards +3 more
Results show that an increase in cell renewal, which is equivalent to a failure of programmed cell death or of differentiation, can lead to the growth of cancers.
NatureInvolvement of the B-lymphoid system in chronic myelogenous leukaemia
237 Citations1980Paul J. Martin, Vesna Najfeld +4 more
Direct evidence is reported here direct evidence that immunoglobulin-synthesizing B lymphocytes can arise from the CML stem cell clone.
BloodPrognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
205 Citations2000Tim H. Brümmendorf, Tessa L. Holyoake +6 more
The data suggest that telomere shortening may serve as a surrogate marker of disease progression in patients with CP CML, supporting a mechanistic link between CML stem cell turnover, genetic instability, and malignant evolution in this disease.
Clinical Cancer ResearchBCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria
141 Citations2007Susan Branford, John F. Seymour +5 more
With prolonged therapy, BCR-ABL continued to decline in most patients and undetectable BCR -ABL was no longer a rare event.
Journal of Clinical OncologyChronic Myeloid Leukemia Stem Cells
138 Citations2008Edward Kavalerchik, Daniel Goff +1 more
Combined therapies targeting aberrant properties of LSC may obviate therapeutic resistance and relapse in advanced phase and therapeutically recalcitrant CML.
LeukemiaElucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia
126 Citations2002Tessa L. Holyoake, Xiaoyan Jiang +3 more
Analysis of purified subsets of primitive CML cells have provided a coherent explanation for this dichotomous behavior of BCR-ABL-positive stem and progenitor cells based on the discovery of an unusual autocrine IL-3/G-CSF mechanism activated in them.
PLoS ONECompartmental Architecture and Dynamics of Hematopoiesis
112 Citations2007David Dingli, Arne Traulsen +1 more
A multi-compartment model of hematopoiesis, designed on the principle of cell flow conservation under stationary conditions, is proposed and the prediction of the average lifetime of a PIG-A mutated clone agrees closely with the experimental results available for the Pig-A gene mutation in healthy adults.
PLoS ONEAllometric Scaling of the Active Hematopoietic Stem Cell Pool across Mammals
104 Citations2006David Dingli, Jorge M. Pacheco
The allometric scaling of the hematopoietic system in a large group of mammalian species using reticulocyte counts as a marker of the active stem cell pool is investigated and predicts that the total number of active stem cells, in an adult mammal, scales with body mass with the exponent ¾.
Cell CycleStochastic Dynamics of Hematopoietic Tumor Stem Cells
99 Citations2007David Dingli, Arne Traulsen +1 more
It is unequivocally demonstrated that stochastic effects related to the finite size of the active stem-cell population have a profound influence on the dynamics of cancer evolution.
BloodA model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector
98 Citations2001Robert C.H. Zhao, Yuehua Jiang +1 more
The transduction of CD34(+) cells with the b3a2-BCR/ABL cDNA recreates most, if not all, phenotypic abnormalities seen in primary CML CD34 (+) cells.
Proceedings of the National Academy of SciencesThe age incidence of chronic myeloid leukemia can be explained by a one-mutation model
94 Citations2006Franziska Michor, Yoh Iwasa +1 more
The CML incidence data are consistent with the hypothesis that the Philadelphia translocation alone is sufficient to cause chronic phase CML, and an alternative hypothesis of cancer initiation requiring only a single mutation is explored.
Journal of Clinical InvestigationUse of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool.
85 Citations1985E. Stephen Buescher, David W. Alling +1 more
The data indicate that in humans there is a highly polyclonal system of hematopoiesis and an estimate of the remaining variation was introduced into a well-known formula to calculate the appropriate number of pluripotent stem cells necessary to support hematopolietic system and a figure exceeding 400 was obtained.
Annals of the New York Academy of SciencesTelomere Length Dynamics in Normal Individuals and in Patients with Hematopoietic Stem Cell‐Associated Disorders
83 Citations2001Tim H. Brümmendorf, Nathalie Rufer +7 more
Results of recent flow FISH studies in patients with selected hematopoietic stem cell‐associated disorders: chronic myelogeneous leukemia (CML) and several bone marrow failure syndromes are described.
Experimental HematologyThe tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
80 Citations2000Stephen B. Marley, Michael W. Deininger +3 more
It is concluded that STI571, like IFN-alpha, preferentially suppresses amplification of CML CFU-GM while sparing normal CF U-GM.
Cytokine & Growth Factor ReviewsThe role of interferon-alpha in the treatment of chronic myeloid leukemia
80 Citations2007Lisa Kujawski, Moshe Talpaz
There is both clinical and laboratory evidence suggesting imatinib therapy alone is not curative in CML, whereas IFN has induced a low but reproducible curative effect in some patients, which may be the basis for the reincorporation of IFN into the management of CML.
DNA repairBCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells
77 Citations2005Artur Słupianek, Michal O. Nowicki +2 more
It is proposed that unfaithful repair of DSBs may contribute to genomic instability in the Philadelphia chromosome-positive leukemias.
HematologyChronic Myeloid Leukemia Stem Cells
64 Citations2008Catriona Jamieson
Accumulating evidence suggests that the acquired BCR-ABL mutation initiates chronic phase CML and results in aberrant stem cell differentiation and survival, which eventually leads to the production of an expanded progenitor population that aberrantly acquires self-renewal capacity resulting in leukemia stem cell (LSC) generation and blast crisis transformation.
Clinical ScienceChronic myeloid leukaemia: stem cell derived but progenitor cell driven
59 Citations2005Stephen B. Marley, Myrtle Y. Gordon
Evidence is presented that, in normal haemopoiesis, less primitive precursor cells retain considerable flexibility in their capacity to undergo self-renewal, allowing them to maintain lineage-specific homoeostasis without inflicting proliferative stress upon the stem cell population.
Proceedings of the National Academy of SciencesNeutral evolution in paroxysmal nocturnal hemoglobinuria
57 Citations2008David Dingli, Lucio Luzzatto +1 more
Simulations in a large virtual population accurately reproduce the known incidence of the disease; and the fit is optimized when the number of stem cells is decreased, reflecting a component of bone marrow failure in PNH.
Cell CycleExamples of Mathematical Modeling: Tales from the Crypt
55 Citations2007Matthew D. Johnston, Carina M. Edwards +3 more
The cell population model by Johnston et al. is used to argue why tumorigenesis is observed to occur in stages with long lag phases between periods of rapid growth, and to identify the key parameters.
British Journal of HaematologyEffects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia
41 Citations2002Stephen B. Marley, Richard J. Davidson +2 more
STI571 + FTI, STi571’+‚AG490 and IFN‐α+ ATRA may be better combination therapies for CML than STI571+“FTI’s”, which are less than additive.
Clinical LeukemiaChronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse
38 Citations2008David Dingli, Arne Traulsen +1 more
A unified framework is developed that models the origin and clonal expansion of CML, the response to abl kinase inhibitors, and relapse upon cessation of therapy and predicts that a small pool of mutated stem cells is enough to drive CML.
British Journal of HaematologyProgenitor cells divide symmetrically to generate new colony‐forming cells and clonal heterogeneity
29 Citations2003Stephen B. Marley, John L. Lewis +1 more
Results show that the kinetics of colony formation respond to extrinsic regulation, and the data best fit a stochastic model of haemopoietic cell development where event probabilities can be modified by extracellular factors.
Leukemia & lymphoma/Leukemia and lymphomaSustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
29 Citations2008Dushyant Verma, Hagop M. Kantarjian +2 more
A patient who was treated with highdose imatinib as frontline therapy for CML in chronic phase, achieved a CCyR and CMR, discontinuedImatinib, and has remained in CMR for 24 months after stopping imatin ib is reported on, believed to be the first published patient with sustained molecular remission after Imatinib discontinuation.
Annals of the New York Academy of SciencesNormalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia
28 Citations2003Tim H. Brümmendorf, Inci Ersöz +16 more
The increase in telomere length under treatment with imatinib reflects a shift from Ph+ to Ph− cells in the PB of patients with CML.
PubMedRoutes to repopulation--a unification of the stochastic model and separation of stem-cell subpopulations.
26 Citations1994M. Y. Gordon, Blackett Nm
It is proposed that the haemopoietic system consists of a hierarchy of clonogenic stem and progenitor cells and that the stochastic effect is superimposed upon these compartments, which means that considerable heterogeneity can exist within major compartments without the need to invoke the existence of numerous subpopulations.
Physical Review EMultiple mutant clones in blood rarely coexist
24 Citations2008David Dingli, Jorge M. Pacheco +1 more
It is concluded that in the absence of genomic instability, acquired hematopoietic disorders due to mutations in multiple genes are most likely very rare events, as multiple mutations typically require much longer development times compared to those associated with a single mutation.
BloodAcquired hematopoietic stem-cell disorders and mammalian size
22 Citations2007J. Viana Lopes, Jorge M. Pacheco +1 more
It is found that the advantage of large mammals at escaping the selective pressure of cancer cells is insufficient to overcome the increased risk of acquiring mutations, which favors smaller stem-cell pools and, consequently, smaller mammals, since these minimize the development of mutations in the active stem- cell pool.
British Journal of HaematologyLineage involvement in chronic myeloid leukaemia: comparison between <i>MBCR/ABL</i><sup>+</sup> and <i>mBCR/ABL</i><sup>+</sup> cases
14 Citations2006Daniel Primo, María Luz Sánchez +7 more
The relationship between different Abelson/breakpoint cluster region (BCR/ABL+) gene rearrangements and the involvement of different haematopoietic cell lineages were investigated in 15 chronic myeloid leukaemia patients, and involvement of both B‐ and NK‐cells was found.